Surmodics Statistics
Total Valuation
Surmodics has a market cap or net worth of $387.37 million. The enterprise value is $389.03 million.
Important Dates
The last earnings date was Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Surmodics has 14.30 million shares outstanding. The number of shares has increased by 0.91% in one year.
| Current Share Class | 14.30M |
| Shares Outstanding | 14.30M |
| Shares Change (YoY) | +0.91% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 3.66% |
| Owned by Institutions (%) | 89.19% |
| Float | 13.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.17 |
| Forward PS | n/a |
| PB Ratio | 3.51 |
| P/TBV Ratio | 8.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.20 |
| EV / EBITDA | 86.18 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.30.
| Current Ratio | 5.14 |
| Quick Ratio | 3.77 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 5.28 |
| Debt / FCF | n/a |
| Interest Coverage | -1.14 |
Financial Efficiency
Return on equity (ROE) is -16.96% and return on invested capital (ROIC) is -1.65%.
| Return on Equity (ROE) | -16.96% |
| Return on Assets (ROA) | -1.44% |
| Return on Invested Capital (ROIC) | -1.65% |
| Return on Capital Employed (ROCE) | -2.66% |
| Revenue Per Employee | $312,532 |
| Profits Per Employee | -$51,062 |
| Employee Count | 389 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, Surmodics has paid $5.29 million in taxes.
| Income Tax | 5.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.76% in the last 52 weeks. The beta is 1.32, so Surmodics's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -15.76% |
| 50-Day Moving Average | 28.98 |
| 200-Day Moving Average | 36.05 |
| Relative Strength Index (RSI) | 40.32 |
| Average Volume (20 Days) | 70,804 |
Short Selling Information
The latest short interest is 476,507, so 3.33% of the outstanding shares have been sold short.
| Short Interest | 476,507 |
| Short Previous Month | 462,327 |
| Short % of Shares Out | 3.33% |
| Short % of Float | 3.66% |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Surmodics had revenue of $121.58 million and -$19.86 million in losses. Loss per share was -$1.40.
| Revenue | 121.58M |
| Gross Profit | 90.78M |
| Operating Income | -3.97M |
| Pretax Income | -9.16M |
| Net Income | -19.86M |
| EBITDA | 4.51M |
| EBIT | -3.97M |
| Loss Per Share | -$1.40 |
Full Income StatementBalance Sheet
The company has $31.15 million in cash and $32.81 million in debt, giving a net cash position of -$1.66 million or -$0.12 per share.
| Cash & Cash Equivalents | 31.15M |
| Total Debt | 32.81M |
| Net Cash | -1.66M |
| Net Cash Per Share | -$0.12 |
| Equity (Book Value) | 110.25M |
| Book Value Per Share | 7.71 |
| Working Capital | 57.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.32 million and capital expenditures -$2.12 million, giving a free cash flow of -$7.44 million.
| Operating Cash Flow | -5.32M |
| Capital Expenditures | -2.12M |
| Free Cash Flow | -7.44M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
Gross margin is 74.67%, with operating and profit margins of -3.27% and -16.34%.
| Gross Margin | 74.67% |
| Operating Margin | -3.27% |
| Pretax Margin | -11.99% |
| Profit Margin | -16.34% |
| EBITDA Margin | 3.71% |
| EBIT Margin | -3.27% |
| FCF Margin | n/a |
Dividends & Yields
Surmodics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.91% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.13% |
| FCF Yield | -1.92% |
Analyst Forecast
The average price target for Surmodics is $43.00, which is 58.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.00 |
| Price Target Difference | 58.73% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 7, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 7, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Surmodics has an Altman Z-Score of 7.62 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.62 |
| Piotroski F-Score | 2 |